KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors targeting PD-1 show limited efficacy in non-small cell lung cancer (NSCLC) due to primary resistance. KIF20A, a cell cycle regulator implicated in chemotherapy resistance, may influence tumor immunity, but its role in anti-PD-1 resistance remains unclear.

Methods

We performed comprehensive bioinformatics analyses to identify KIF20A as a resistance-associated hub gene. Clinical validation was performed in 106 NSCLC patients receiving anti-PD-1 therapy. KIF20A protein expression was assessed by immunohistochemistry (IHC), and tumor microenvironment (TME) profiling was performed using multiplex immunofluorescence (mIHC). Statistical analyses included chi-square tests, Kaplan-Meier survival, Cox regression, and Spearman correlation.

Res

SUBMITTER: Su T 

PROVIDER: S-EPMC12636182 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature